title: CSF myelin basic protein, IgG and IgM levels in 101 MS patients before and after treatment with high-dose intravenous methylprednisolone.
abstract: A total of 101 patients (62 women; 39 men) with definite MS were treated with 1000 mg methylprednisolone (MP) intravenously for 10 consecutive days. Immediately before and after MP treatment clinical scoring (Kurtzke's Expanded Disability Status Scale) and CSF analysis were performed. Before MP treatment CSF MBP, IgG and IgM immunoglobulin levels (CSF Ig, index and intrathecal synthesis) were significantly elevated. The mean CSF MBP levels were significantly higher in the relapsing-remitting (RR) and chronic progressive MS patients with relapses (CP + RR) than in the CP group without a RR disease course, respectively 2.1, 2.3 and 1.5 micrograms/l. A weak positive correlation was found between CSF MBP level and EDSS in the RR MS group (r = 0.34). CSF MBP was significantly correlated with IgM index (r = 0.36), IgM synthesis (r = 0.26), but not with the IgG levels. Therefore demyelination seems to be related to intrathecal IgM production. After MP treatment mean (median) EDSS decreased from 4.4 (4.0) to 3.3 (3.0). Except for Q albumin and IgM index, all CSF immunoglobulin levels decreased significantly after MP. The mean CSF MBP returned to reference values. In the RR group the decrease in CSF MBP was significantly correlated with the change in EDSS (r = 0.39). CSF MBP seems to be a good parameter for disease activity in relapsing MS. Following treatment CSF MBP was found to be related with the change in IgM index (r = 0.30). MP treatment reduces CSF MBP and intrathecal IgM in a similar way indicating a relation between these 2 parameters.
authors.affiliation: Department of Neurology, University Hospital, Nijmegen, The Netherlands.
authors.forename: S T
authors.initials: ST
authors.lastname: Frequin
authors.forename: F
authors.initials: F
authors.lastname: Barkhof
authors.forename: K J
authors.initials: KJ
authors.lastname: Lamers
authors.forename: O R
authors.initials: OR
authors.lastname: Hommes
authors.forename: G F
authors.initials: GF
authors.lastname: Borm
mesh_terms: D000328:Adult; D001812:Blood-Brain Barrier / Q000187:drug effects / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000134:cerebrospinal fluid*; D007075:Immunoglobulin M / Q000134:cerebrospinal fluid*; D007262:Infusions, Intravenous; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage*; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000276:immunology*; D004676:Myelin Basic Protein / Q000134:cerebrospinal fluid*; D009460:Neurologic Examination / Q000187:drug effects; D012016:Reference Values
chemical_list: D007074:Immunoglobulin G; D007075:Immunoglobulin M; D004676:Myelin Basic Protein; D008775:Methylprednisolone